Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
Globe Newswire•19/10/2026•08:00 ET
0
Key Highlights
- ➤Global Q3 preliminary net revenue €9.2 million, up 19% sequentially
- ➤U.S. Q3 preliminary net revenue €6.7 million, up 29% sequentially
- ➤2026 revenue guidance cut to €33 million-€35 million from €36 million-€40 million
- ➤ACCCESS study achieved 77.2% 12-month AHI responder rate in CCC patients
- ➤Nyxoah submitted FDA PMA supplement seeking Genio indication expansion to CCC patients
Expert Statements
Liam Kelly, Chief Executive Officer of Nyxoah
“We delivered 29% sequential revenue growth in the U.S. in the third quarter, and our International business performed in line with our expectations. While we are disappointed to adjust our full year revenue guidance to €33 to €35 million, we are still pleased with the acceleration in growth. We continue to expect improving U.S. growth in Q4 compared to Q3 2026. The ramp in U.S. sales is more reflective of historical ramps for a new technology, as physicians and centers build experience with Genio. Our foundations are strong. Physicians and OSA patients want a choice in hypoglossal nerve stimulation therapy. We see this demand in the growing number of active accounts and trained surgeons in the U.S., and in the positive feedback we receive on the Genio system. We remain confident in our ability to drive durable growth in the U.S. and to improve care for OSA patients.”
Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
U.S. net revenue grows 29% sequentially, driving third quarter global preliminary net revenue of €9.2 million PMA supplement submitted to the FDA to expand Genio’s U.S. indication to Complete Concentric Collapse patients
Get started
Create a free account to read the full story.